J&J; Receives Subpoena for Schizophrenia Drug
Johnson & Johnson said it received a U.S. subpoena regarding its drug Risperdal, the most prescribed schizophrenia medicine in the U.S.
The subpoena for the company’s Janssen Pharmaceutica division came from investigators for the Office of Personnel Management, the New Brunswick, N.J.-based company said.
The government agency oversees health benefits for federal employees. Risperdal has been at the center of lawsuits filed by Johnson & Johnson, which is trying to block other firms from making generic copies of the medicine. A patent on the drug expires in 2007.
Johnson & Johnson shares fell 5 cents to $53 on the NYSE.
Start your day right
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
You may occasionally receive promotional content from the Los Angeles Times.
